Clinical Trial

The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated February 24, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to investigate the effect of Gliatamin (chonline alphoscerate) on depressive mood in type 2 diabetes patients and demonstrate the impact of improved depressive mood could be influence the patient's quality of life and glycemic control.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2017-02-16; most recent amendment 2025-02-20.
Trial Details
NCT Number NCT03059069
Lead Sponsor Yonsei University
Conditions Type2 Diabetes With Depressive Mood
Enrollment 60 participants
Start Date 2016-06-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-24